Interpace Enters Strategic Partnership Agreement with Genecast Biotechnology to Partner with Biopharma Solutions in China
September 16 2019 - 6:55AM
Interpace Diagnostics Group, Inc.’s subsidiary, Interpace BioPharma
Inc. (“Interpace”, “Interpace BioPharma” or the
“Company”) today announced that it has entered into a
partnership agreement to jointly develop, promote, and offer
translational studies and clinical trial solutions to biotech and
pharmaceutical companies with Genecast (Beijing) Biotechnology Co.
Ltd (“Genecast”) of the Peoples Republic of China (“PRC”). Genecast
is a leader in offering diagnostic products and services in the
field of oncology and providing a wide range of diagnostic services
to pharmaceutical and biotech companies in the PRC. According to
the agreement, Interpace BioPharma will perform services worldwide
except in the PRC, while Genecast will provide services in the PRC.
Michael McCartney, Chief Commercial Officer of
Interpace BioPharma, commented, “Genecast has an impressive,
well-established menu of tumor profiling and clinical testing
services and is the optimal partner to collaborate with our mutual
capabilities to bring a global footprint to our biopharma solutions
offerings. This collaboration is in line with our business strategy
of driving sustainable, long-term growth and profitability by
leveraging our unique capabilities.”
Du Bo, Co-Founder and CEO of Genecast, said, “As
China plays a more important role in innovative drug development,
global multi-center trials with programs in China have become a
critical strategy of drug developers. This partnership with
Interpace will strengthen our capabilities to provide our customers
with high-quality, streamlined one-stop testing services globally
and is in line with our strategy of helping pharmaceutical and
biotech companies to accelerate their biomarker-driven drug
development and drive precision medicine forward.”
About Interpace
Interpace is a leader in enabling personalized
medicine, offering specialized services along the therapeutic value
chain from early diagnosis and prognostic planning to targeted
therapeutic applications.
Interpace’s Biopharma Business is a market
leader in providing pharmacogenomics testing, genotyping, and
biorepository services to the pharmaceutical and biotech
industries. The Biopharma Business also advances personalized
medicine by partnering with pharmaceutical, academic, and
technology leaders to effectively integrate pharmacogenomics into
their drug development and clinical trial programs with the goals
of delivering safer, more effective drugs to market more quickly,
and improving patient care.
Interpace’s Diagnostic Business is a fully
integrated commercial and bioinformatics business unit that
provides clinically useful molecular diagnostic tests,
bioinformatics and pathology services for evaluating risk of cancer
by leveraging the latest technology in personalized medicine for
improved patient diagnosis and management. Interpace has four
commercialized molecular tests and one test in a clinical
evaluation process (CEP).
For more information, please visit Interpace’s
website at www.interpacediagnostics.com.
Genecast (Beijing) Biotechnology Co. Ltd.
Genecast is a leader in offering diagnostic
products & services in the field of oncology and providing a
wide range of diagnostic services to pharmaceutical and biotech
companies in the Peoples Republic of China (PRC). Genecast’s
laboratories have met all applicable standards for accreditation
including accreditation from the CAP and earned top marks in a
number of external quality assessments carried out by CAP, EMQN,
the Clinical Test Center of the National Health Commission of China
and Center of Clinical Laboratories of Shanghai.
Genecast has formed collaborations with more
than 20 pharmaceutical and biotech companies in providing
comprehensive pre-clinical and clinical testing services.
For more information, please visit Genecast’s
website at www.genecast.com.cn.
Media Contact:
Dan ChenGenecast (Beijing)
Biotechnologychen.dan@genecast.com.cn
Forward Looking Statements on Behalf of
Interpace
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, relating to the
Company’s future financial and operating performance. The Company
has attempted to identify forward looking statements by terminology
including “believes,” “estimates,” “anticipates,” “expects,”
“plans,” “projects,” “intends,” “potential,” “may,” “could,”
“might,” “will,” “should,” “approximately” or other words that
convey uncertainty of future events or outcomes to identify these
forward-looking statements. These statements are based on current
expectations, assumptions and uncertainties involving judgments
about, among other things, future economic, competitive and market
conditions and future business decisions, all of which are
difficult or impossible to predict accurately and many of which are
beyond the Company’s control. These statements also involve known
and unknown risks, uncertainties and other factors that may cause
the Company’s actual results to be materially different from those
expressed or implied by any forward-looking statement.
Additionally, all forward-looking statements are subject to the
“Risk Factors” detailed from time to time in the Company’s most
recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q
and other SEC filings. Because of these and other risks,
uncertainties and assumptions, undue reliance should not be placed
on these forward-looking statements. In addition, these statements
speak only as of the date of this press release and, except as may
be required by law, the Company undertakes no obligation to revise
or update publicly any forward-looking statements for any
reason.
INTERPACE CONTACTS: Investor Relations Joseph
Green, Edison Group jgreen@edisongroup.com
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Sep 2023 to Sep 2024